Landmark studies have demonstrated the safety and efficacy of implantable cardioverter-defibrillators (ICDs) in selected stable ambulatory patients with heart failure (HF) with a reduced ejection fraction receiving optimal medical therapy. It is not known whether a recent hospitalization for HF before ICD placement is associated with subsequent outcomes.
A lthough the prognosis of ambulatory patients with heart failure with a reduced ejection fraction (HFrEF) has been revolutionized by the development of guideline-directed medical therapies, there are >1 million admissions for heart failure (HF) annually in the United States. [1] [2] [3] [4] [5] [6] Hospitalization is a particularly important inflection point in the natural history of HF; early postdischarge readmission and mortality rates may be as high as 30% and 15%, respectively. 7 However, despite the attendant morbidity and mortality of hospitalizations for HF, landmark trials for evidencebased medications and devices enrolled stable outpatients on optimal medical therapy, [8] [9] [10] and it is uncertain whether the time from last hospitalization for HF to implantable-cardioverter defibrillator (ICD) placement is associated with outcomes. [11] [12] [13] The best time for implementing HF therapies is particularly relevant to ICD placement, which is known to pose additional initial risk to patients when implanted during an index admission for HF. 14 The National Cardiovascular Data Registry's (NCDR) ICD Registry provides a unique opportunity to systematically analyze in-hospital adverse events and postdischarge outcomes based on timing of ICD placement from last hospitalization for HF. Specifically, the objectives of this analysis were to systematically describe the clinical characteristics, periprocedural complications, and postprocedural readmissions and mortality based on the timing of ICD placement for primary prevention of sudden cardiac death (SCD) from the last hospitalization for HF.
METHODS

Data Sources
Patient and device implantation data were obtained from the NCDR ICD Registry. The data cannot be made available to other researchers by the authors for purposes of reproducing the results or replicating the procedure, because, by contract with participating sites, analyses of NCDR data are to be performed by contracted data analytic centers. Demographics, clinical characteristics, and procedural data were collected using standardized definitions. 15, 16 Data on periprocedural complications are recorded in the NCDR ICD Registry, whereas 30-day and 90-day complications and reoperations were obtained by linking the NCDR ICD Registry with the Medicare Inpatient Institutional Claims, Outpatient Institutional Claims, and Master Summary Beneficiary Files. These databases contain claims for inpatient admissions, outpatient procedures, and enrollment and vital status for Medicare fee-for-service patients. The study protocol was approved by the institutional review board and ethics committee at each participating site. All patients provided written informed consent.
Study Population
All patients enrolled in the NCDR ICD Registry with a diagnosis of HF and an ejection fraction (EF) ≤35% undergoing a new ICD implant for primary prevention between January 1, 2010 and December 31, 2014 were considered for inclusion. Relevant exclusion criteria included patients currently hospitalized for a nonelective reason other than HF, acute myocardial infarction within 40 days or revascularization within 90 days, prior ventricular tachycardia/ventricular fibrillation arrest, arrhythmogenic syndromes with an increased risk of SCD (eg, Brugada, catecholaminergic polymorphic ventricular tachycardia, and long-QT syndrome), epicardial lead placement, lead only procedures, and device replacements.
The NCDR ICD Registry was linked to Medicare data by social security number, date of birth, and sex. Only patients matching a beneficiary on all 3 criteria were included. Our cohort was further restricted to patients enrolled in Medicare fee-for-service for at least 3 months before and 3 months following their procedure to permit the ascertainment both of antecedent hospitalizations and the outcomes of interest.
Outcomes
Composite and cause-specific event rates were calculated for complications occurring during the periprocedural and 30-and 90-day periods. Periprocedural complications were ascertained based on the NCDR ICD Registry case report form completed at the point-of-care by the treating physician and ancillary support staff. To identify 30-day and 90-day device-related complications, reoperations were first identified by using codes from the International Classification of Diseases, Ninth Revision, Clinical Modification and Current Procedural Terminology, respectively, for inpatient and outpatient procedures. 17 The subset of reoperations attributable
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What Is New?
• Landmark clinical trials have demonstrated the safety and efficacy of implantable cardioverterdefibrillators in selected stable ambulatory patients who have heart failure with a reduced ejection fraction.
• However, the optimal timing of implantable cardioverter-defibrillator placement for primary prevention following an index hospitalization for heart failure remains unknown.
What Are the Clinical Implications?
• This study found that patients currently or recently admitted for a diagnosis of heart failure who received a primary prevention implantable cardioverter-defibrillator experienced a higher adjusted rate of periprocedural complications and were at increased risk of readmission or death independent of traditional risk factors.
• These data highlight the need for additional prospective, real-world, pragmatic, comparative effectiveness studies to assess the relative risks and benefits of an early versus delayed strategy for implantable cardioverter-defibrillator placement following hospitalization for heart failure.
to device-related complications was then determined based on whether the primary diagnosis was the result of mechanical complication of the device, infection (ie, device infection, endocarditis, or systemic infection), ICD pocket-related complication, or other complication related to perforation, inflammation, and venous obstruction or thromboembolism. 17 In addition, device-related complications not requiring reoperation were identified as hospitalizations (ie, inpatient admissions, observation stays, and emergency department visits) with a primary diagnosis consistent with a device-related complication (ie, International Classification of Diseases, Ninth Revision, Clinical Modification codes) in the absence of a procedure code indicating device reoperation. Devicerelated complications not resulting in an acute care episode (ie, inpatient admissions, observation stays, and emergency department visit) or reoperation in an inpatient or ambulatory setting were not included.
Statistical Analysis
Study participants were grouped based on the timing of ICD placement from last hospitalization for HF (ie, currently hospitalized for HF versus hospitalized for HF ≤3 months versus hospitalized for HF >3 months previously or no previous admission for HF) identified using admissions from inpatient institutional claims. Three months was selected as the cutoff between a recent and more remote hospitalization for HF because this is the timeframe that is generally recommended in the guidelines for reassessing clinical status and EF following the implementation of optimal medical therapy and coronary revascularization (ie, percutaneous coronary intervention or coronary artery bypass grafting). Baseline clinical characteristics were expressed as percentages for categorical variables and means and standard deviations for continuous variables. The unadjusted periprocedural, 30-day, and 90-day complication event rates were calculated as an incidence rate (ie, number of events/number of procedures) with 95% CI. In addition, as a sensitivity analysis, aggregate periprocedural, 30-day, and 90-day complication rates were determined by device type (ie, single-chamber ICD versus dual-chamber ICD versus cardiac resynchronization therapy-defibrillator [CRT-D]). Comparisons of unadjusted composite and cause-specific event rates were adjusted for multiple comparisons by using the Holm procedure.
Multivariable logistic regression using generalized estimating equations using an exchangeable working correlation structure was utilized to assess the association between the timing of ICD placement from last hospitalization for HF and in-hospital (ie, any adverse event and mortality), 30-day (ie, all-cause mortality, all-cause readmissions, and cardiovascular [CV] readmissions), and 90-day (ie, all-cause mortality, all-cause readmissions, and CV readmissions) outcomes. For each model, odds ratios (ORs) with 95% CIs were calculated. Models were adjusted for potential confounders including age, sex, EF, New York Heart Association functional class, QRS duration, systolic blood pressure, serum sodium, serum creatinine, blood urea nitrogen, hemoglobin, cardiac (ie, hypertension, cerebrovascular disease, previous percutaneous coronary intervention, prior coronary artery bypass graft, syncope, and previous cardiac arrest) and noncardiac comorbidities (ie, diabetes mellitus, chronic obstructive pulmonary disease, and end-stage renal disease requiring dialysis), and device type (ie, single-chamber ICD versus dual-chamber ICD versus CRT-D).
Covariates included in each model were selected by using a stepwise selection approach. The probability of entry into the model was set at P≤0.50 and probability of removal P≥0. 10 . Before modeling, missing continuous and categorical variables were imputed using fully conditional specification methods. 18 Dichotomous variables with missing values were assumed to be absence of the disease. Missingness rates ranged from 0% to 2.1% with the large majority of variables missing <1%. Additional analyses were performed to assess for an interaction between device type (ie, single-chamber ICD versus dual-chamber ICD versus CRT-D) and timing of ICD placement from last hospitalization for HF and outcomes.
All analyses were 2-sided and a P<0.05 was set as the threshold for statistical significance. Statistical analyses were performed using SAS software, version 9.4 (SAS Institute).
Funding Source and Article Preparation
The American College of Cardiology (Washington, DC) provides ongoing financial and material support for the NCDR ICD Registry. Database management and statistical analysis were performed by the Center for Outcomes Research and Evaluation, Yale University School of Medicine (New Haven, CT). The authors take responsibility for the article's integrity and had authority over its preparation and the decision to publish.
RESULTS
A total of 283 382 patients with HFrEF undergoing initial ICD placement for primary prevention of SCD were identified ( Figure 1 ). The primary reasons for exclusion were currently hospitalized for a nonelective reason other than HF (n=36 684), acute myocardial infarction within 40 days or revascularization within 90 days (n=12 218), and epicardial lead placement (n=9219). After linking the NCDR ICD Registry cohort to Medicare data, the final analytic cohort included 81 180 patients. Patients were assigned to the following groups based on the timing of ICD placement from last hospitalization for HF: currently hospitalized for HF (n=11 563, 14%), hospitalized for HF within 3 months (n=6252, 8%), or hospitalized for HF >3 months previously or no previous admission for HF (n=63 365, 78%).
Patient Characteristics at Implantation
Patients currently or recently hospitalized for HF tended to be nonwhite (25% versus [versus] 22% versus 15%) in comparison with patients without a recent admission for HF (Table 1) . These patients also tended to have a lower EF (23±7 versus 24±7 versus 26±6), were more likely to report New York Heart Association functional class III/IV symptoms (85% versus 78% versus 62%), and had a higher burden of cardiac (ie, atrial fibrillation) and noncardiac (ie, diabetes mellitus and chronic obstructive pulmonary disease) comorbidities. Patients
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currently or recently admitted for HF also had a lower hemoglobin (12.1±1.9 g/dL versus 12.5±1.8 g/dL versus 13.2±1.7 g/dL) and worse renal function as measured by blood urea nitrogen (32±16 versus 31±15 versus 25±12) in comparison with patients without a recent hospitalization for HF. Among patients currently or recently hospitalized for HF, the rate of prescription of angiotensin converting-enzyme inhibitors/angiotensin receptor blockers was lower (72% versus 75% versus 81%), and they were more likely to be receiving loop diuretics (81% versus 86% versus 68%) and digoxin (24% versus 22% versus 17%). Finally, patients receiving a primary prevention ICD during or within 3 months of an index admission for HF were more likely to receive a CRT-D device (59% versus 60% versus 53%) as opposed to a single-chamber or dual-chamber ICD.
Periprocedural and Postprocedural Complication Rates
The composite periprocedural complication rate was 1.47% (95% CI, 1.39%-1.56%) ( Table 2 ). Among patients currently hospitalized for HF, hospitalized for HF within 3 months, or hospitalized for HF >3 months previously or no previous admission for HF, respectively, the composite periprocedural complication rate was 2.60% (2.32%-2.91%), 1.71% (1.40%-2.06%), and 1.25% (1.16%-1.33%) (P<0.001). This finding was driven by a higher rate of stroke/transient ischemic attack, myocardial infarction (MI), cardiac arrest, and in-hospital death as shown in Table 2 . With the notable exception of ICD pocket hematoma, patients currently or recently hospitalized for HF experienced similar rates of other complications including cardiac perforation, cardiac venous dissection, pericardial tamponade, pneumothorax, and hemothorax (P≥0.05 for all comparisons). The composite 30-day complication rate was 2.11% (2.01%-2.22%). Among patients currently hospitalized for HF, hospitalized for HF within 3 months, or hospitalized for HF >3 months previously or no previous admission for HF, respectively, the composite 30-day complication rate was 5.24% (4.82%-5.67%), 3.30% (2.86%-3.78%), and 1.42% (1.33%-1.52%) (P<0.001). The higher 30-day complication rate observed among patients currently or recently hospitalized for HF was driven principally by a higher mortality rate and, to a lesser extent, ICD pocket-related complications and pneumothorax/hemothorax/pleural effusion not requiring reoperation as shown in Table 2 . However, there was no difference in complications requiring reoperation including pocket-related issues, pneumothorax/hemothorax/pleural effusion, and pericardial effusion/tamponade (P≥0.05 for all comparisons).
Similarly, the composite 90-day complication rate was 5.18% (5.02%-5.35%). Among patients currently hospitalized for HF, hospitalized for HF within 3 months, or hospitalized for HF >3 months previously or no previous admission for HF, respectively, the composite 90-day complication rate was 7.75% (7.24%-8.29%), 6.25% (5.64%-6.91%), and 4.61% (4.44%-4.79%) (P<0.001). In addition, there was no difference in 90-day complications requiring reoperation. However, in comparison with patients with no recent hospitalization for HF, patients currently or recently hospitalized Left ventricular ejection fraction, mean (SD)
26 (6) 23 (7) 24 (7) 26 (6) New York Heart Association class 
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for HF experienced higher 90-day rates of infections including device infections not requiring reoperation and endocarditis and other systemic infections irrespective of operative status as shown in Table 2 .
A sensitivity analysis was performed to look at the periprocedural, 30-day, and 90-day complication rate by device type (ie, single-chamber ICD versus dualchamber ICD versus CRT-D). In general, the trends in complication rates were similar in all 3 groups (Table I in the online-only Data Supplement). Regardless of device type, patients currently hospitalized for HF or hospitalized for HF within 3 months were at higher risk of periprocedural, 30-day, and 90-day complications in comparison with patients hospitalized for HF >3 months previously or with no previous admission for HF. The higher 30-day and 90-day overall complication rates were driven by complications not requiring reoperation.
Timing From Last Hospitalization for HF and Outcomes
After multivariable adjustment, patients currently hospitalized for HF had higher odds of any adverse event (odds ratio, 1.61; 95% CI, 1.38-1.87; P<0.001) and inhospital mortality (odds ratio, 5.56; 95% CI, 3.68-8.39; P<0.001) in comparison with patients without a hospitalization for HF within the past 3 months (Table 3 , Figure 2) . In contrast, patients hospitalized for HF within the past 3 months had higher odds of in-hospital mortality (odds ratio, 2.79; 95% CI, 1.59-4.90; P<0.001) but not any adverse event (P=0.195).
Patients currently or recently hospitalized for HF were at increased odds of all-cause mortality, all-cause admissions, and CV admissions within both 30 and 90 days in comparison with patients without a recent admission for HF (Figures 3 and 4) . It is noteworthy that the odds of all-cause and CV-related morbidity and mortality were highest among patients undergoing ICD placement for primary prevention during a hospitalization for HF.
In addition, a sensitivity analysis was performed to look at in-hospital, 30-day, and 90-day outcomes based on timing from last hospitalization for HF stratified by device type (ie, single-chamber ICD versus dual-chamber ICD versus CRT-D). The results were similar when stratified by device type for in-hospital and 30-day outcomes (Table II in the online-only Data Supplement). In contrast, patients undergoing placement of a CRT-D device and single-chamber ICD for primary prevention during index hospitalization were, respectively, at higher risk of all-cause 90-day admissions and CV 90-day admissions in comparison with patients admitted for HF within the past 3 months (Table III in 
DISCUSSION
The objectives of this post hoc analysis of the NCDR ICD Registry were to systematically describe the clinical characteristics, periprocedural complications, and postprocedural outcomes based on the timing of ICD placement for primary prevention from last hospitalization for HF. Approximately 20% of patients had an ICD placed during a hospitalization for HF or within 3 months of admission for a primary diagnosis of HF. Patients currently or recently hospitalized for HF tended to have a lower EF, were more symptomatic, had a higher burden of cardiac and noncardiac comorbidities, and were less likely to be treated with an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker at baseline. Patients currently or recently hospitalized for HF had higher composite periprocedural, 30-day, and 90-day complication rates driven by a higher rate of stroke/angiotensin receptor blocker, MI, cardiac arrest, death, and minor access site and pocket-related complications not requiring reoperation. Finally, patients currently or recently hospitalized for HF were at higher risk of in-hospital mortality and postprocedural readmission or death independent of traditional risk factors.
Data from the Get With the Guidelines-HF registry suggest that, among patients hospitalized for a primary diagnosis of HFrEF, <25% had an ICD in situ. 19 It has also been well-documented in clinical trials of acute HF that ICDs may be underutilized and that substantial geographic disparities exist. [20] [21] [22] [23] [24] Although we found that only ≈20% of patients underwent initial ICD placement for primary prevention within 3 months of a hospitalization 
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for HF and implanting a primary prevention ICD is associated with worse outcomes, hospitalization represents an opportunity to review background guideline-directed medical and device-based therapies for HF and refer patients for consideration of ICD placement in the ambulatory setting. A recent meta-analysis of landmark clinical trials of pharmacotherapy in HF found that among patients with HFrEF without an ICD, the incidence of SCD has declined from 2.4% to 1.0% at 90 days as a result of the cumulative benefit of evidence-based medications. 25, 26 In contrast, it is known that following an index hospitalization for HFrEF, the incidence of SCD may be as high as 2% within 30 days and >25% of deaths may be attributable to fatal arrhythmias. [27] [28] [29] Observational studies of patients with HF receiving ICD during an index HF hospitalization have shown significantly better survival than otherwise eligible patients that have not received an ICD during the HF hospitalization. [11] [12] [13] However, because the present study only compared outcomes among patients receiving an ICD, the magnitude of benefit, risks, and risk/benefit ratio related to timing of ICD implant cannot be determined.
The data presented in this analysis of the NCDR ICD Registry suggest that patients currently or recently hospitalized for HF had higher aggregate periprocedural, 30-day, and 90-day complication rates than patients without a recent hospitalization for HF. In addition, the differences in the periprocedural, 30-day, and 90-day complication rates were driven by a higher rate of stroke/transient ischemic attack, MI, cardiac arrest, and death with a few notable exceptions. However, because all these risks have been previously shown to be increased in patients who have HFrEF with a current or recent hospitalization, irrespective of device placement, they may be entirely unrelated. Potentially more concerning is the higher incidence of device infections and endocarditis seen at 90 days, which may be explained by multiple factors including, but not limited to, the acuity of illness, prolonged hospitalization/deconditioning, exposure to nosocomial pathogens, and indwelling intravenous lines and urinary catheters. Given the attendant morbidity and mortality associated with CV implantable electronic device infections, strategies to mitigate this risk, including patient selection, It is important to note that, after adjusting for potential confounders, patients currently or recently hospitalized for HF undergoing ICD placement for primary prevention were also at higher risk for all-cause death and readmission than patients without a recent hospitalization for HF. Although this is not entirely unexpected, it raises the question of whether a strategy of early (ie, during hospitalization or soon after discharge) versus delayed (ie, ≥3 months) ICD placement is indicated. Although ICDs may be underutilized in patients hospitalized for HF and this patient population is at relatively higher risk for SCD, providers and patients must assess the competing risks versus benefits in making treatment decisions. Patients admitted for a primary diagnosis of HF experience an exceptionally poor shortterm prognosis and >40% of deaths occurring in the postdischarge vulnerable phase may be attributable to progressive HF and cardiogenic shock. 27 In addition, an unknown proportion of the patients experiencing SCD early postdischarge may be attributable to nonshockable rhythms (ie, asystole or pulseless electric activity). 30 It is plausible that, because of the overall dismal prognosis and competing risk of deaths, patients hospitalized for HF may behave similarly to the post-MI population in which early ICD placement has not been shown to beneficial. 31, 32 Thus, there is a strong theoretical rationale for a strategy trial to determine the optimal timing of ICD placement for primary prevention from last hospitalization for HF.
Several limitations of this study should be mentioned. First, this study was conceived post hoc and the timing of ICD placement was not randomized. As a result, the relationships could reflect unmeasured or residual confounding. Second, comparisons were not made with a comparable cohort of patients eligible for ICD placement that did not receive this therapy. Third, Medicare claims data were used to identify 30-and 90-day complications, and claims data may be inaccurate and lack the complexity and granularity in comparison with patient data extracted directly from clinical records. However, Medicare Claims Data are the only available data source that has 
nationwide coverage, permitting follow-up of a large cohort of patients. Fourth, this study included only Medicare fee-for-service patients aged ≥65 years and may not be generalizable to a younger HF population. Fifth, this study likely underestimates the overall burden of morbidity because events not leading to an acute care episode or reoperation (ie, inappropriate shocks) were not included. Finally, the rate of new device implants for which these data are most relevant (HFrEF currently or recently hospitalized for a primary diagnosis of HF) is declining.
In conclusion, ≈20% of patients undergoing ICD placement for primary prevention were currently or recently hospitalized for HF. The aggregate periprocedural, 30-day, and 90-day complication rates were higher among this subset of patients and driven by a higher rate of stroke/transient ischemic attack, MI, cardiac arrest, and death. Additional research is required to clarify the signal of increased pocket infection, endocarditis, and other systemic infections, and to identify approaches to mitigating the overall risk of infection in patients hospitalized for HF, as well. Finally, given the highlighted safety concerns and the overall poor short-term prognosis and high competing risk of death because of progressive pump failure in patients hospitalized for HF, future prospective, real-world, pragmatic, comparative effectiveness studies should be conducted to define the optimal timing of ICD placement for primary prevention from the last hospitalization for HF.
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